🔗 Permalink

Inventor profile of:

Lars Röse

City:

Berlin

Country:

Germany

Published Applications:

13

Last publication date:

2024-09-05

Top Assignees for applications by Lars Röse

The entities that hold a legal rights for patent applications filed by inventor Röse Lars:

Bayer Aktiengesellschaft 10 Leverkusen, Germany
Bayer Pharma Aktiengesellschaft 9 Berlin, Germany
Deutsches Krebsforschungszentrum 6 Heidelberg, Germany
Deutsches Krebsforschungszentrum 1 , Germany
DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) 1 Heidelberg, Germany
Bayer HealthCare LLC 1 Whippany, NJ United States
Compugen Ltd. 1 Holon, Israel

Recent patent applications by Röse Lars

Lars Röse from Berlin, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-09-05

US20240294505A1

Chemistry; metallurgy

2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER

#2 | 2023-04-20

US20230121195A1

Chemistry; metallurgy

2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

#3 | 2020-11-26

US20200369769A1

Chemistry; metallurgy

ILDR2 antagonists and combinations thereof

#4 | 2020-09-24

US20200299269A1

Chemistry; metallurgy

Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

#5 | 2020-09-17

US20200289509A1

Human necessities

2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

#6 | 2020-09-10

US20200283402A1

Chemistry; metallurgy

3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides

#7 | 2020-09-10

US20200283395A1

Chemistry; metallurgy

2-phenylpyrimidine-4-carboxamides as AHR inhibitors

#8 | 2020-07-30

US20200237757A1

Human necessities

3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides

#9 | 2020-06-18

US20200188372A1

Human necessities

Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

#10 | 2020-06-11

US20200179354A1

Human necessities

Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

#11 | 2020-05-21

US20200155674A1

Human necessities

COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER

#12 | 2015-04-30

US20150119372A1

Human necessities

APPLICATION OF 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE SYSTEMS IN THE TREATMENT OF MENORRHAGIA, AS WELL AS INTRAUTERINE SYSTEMS CONTAINING 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE FOR TREATING UTERINE BLEEDING DISORDERS

#13 | 2015-03-05

US20150065472A1

Human necessities

INTRAUTERINE APPLICATION OF 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE SYSTEMS, INTRAUTERINE SYSTEMS CONTAINING 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE, AS WELL AS THE USE THEREOF IN CONTRACEPTION AND GYNAECOLOGICAL THERAPY

InventorID:

1088498 ⎘